Monday, June 4, 2018
Marriott Marquis Washington, DC
Independence E-G, Level 4
6:00 pm - 6:30 pm||Registration and Dinner
6:30 pm - 8:00 pm||CME-certified Symposium
Slide to view more
Biosimilars are very much alike but not identical to an FDA-approved reference biologic compound, with no meaningful differences in quality, safety, or efficacy. Used widely in Europe since 2006, the first biosimilar agent for use in the United States was approved in March 2015, and now several biosimilars are FDA-approved. As more biosimilars become available for use in the United States, all members of the multidisciplinary care team will require education on the appropriate incorporation of these agents into existing treatment paradigms. The faculty of this CME activity will provide an overview of biosimilars as well as a review of the latest safety and efficacy data regarding the use of biosimilars relevant to gastroenterology.